ATI ADULT HEALTH 1

Correct Answer: Hyperglycemia.

When Total Parenteral Nutrition (TPN) is initiated, it is crucial to start it at a slow rate to prevent hyperglycemia, which can occur due to the rapid infusion of glucose and other nutrients. Here’s why:

Hyperglycemia: The primary concern with initiating TPN at a fast rate is the risk of hyperglycemia (high blood sugar).

Since TPN contains high concentrations of glucose, starting the infusion too quickly can overwhelm the body’s ability to process and regulate blood sugar, leading to spikes in glucose levels.

Gradually increasing the infusion rate allows the body to adapt and helps prevent this complication.

Why the other options are incorrect:

Infection: Infection is a concern with TPN, but it is primarily related to the central venous catheter (CVC) used to administer the nutrition, not the rate at which TPN is infused. The slow infusion rate is not directly aimed at preventing infection.

Discomfort: While patients might experience discomfort from the catheter or the TPN itself, the slow rate of infusion is not primarily intended to alleviate discomfort. The goal is to prevent complications like hyperglycemia.

Air embolism: An air embolism can occur if air enters the TPN line, but the infusion rate is not typically adjusted to prevent air embolism. Proper management of the catheter and the system is more important in preventing this rare complication.

Summary:

The main reason for starting TPN at a slow rate is to prevent hyperglycemia, as rapid infusion of glucose can lead to high blood sugar. Proper management helps ensure a smooth transition and reduces the risk of complications related to the rapid infusion of nutrients.

Correct Answer: Temperature

Among the listed findings, the elevated temperature (101°F) would be of most concern to the nurse.

A fever can be indicative of infection, which is particularly concerning in patients with type 2 diabetes because infections can cause hyperglycemia and lead to complications.

Infections can also make it more difficult for the body to manage blood sugar levels, and patients with diabetes are more prone to infections due to poor circulation and immune dysfunction associated with the condition.

Why the other options are Wrong:

Blood pressure (140/84 mmHg):

Elevated blood pressure is a concern, but it is not as immediately life-threatening as a fever. High blood pressure is a common comorbidity in patients with diabetes and should be addressed over time, but it does not require urgent intervention unless it’s significantly elevated or associated with symptoms like dizziness or chest pain.

Blood glucose (120 mg/dL):

A fasting blood glucose of 120 mg/dL is slightly above the normal range for a fasting glucose level, which typically should be under 100 mg/dL. However, it is not excessively high and doesn't indicate an acute problem. While it should be monitored, it is not as urgent as a fever.

Respirations (22):

A respiratory rate of 22 is on the higher end of normal, but it is not severely elevated. It may indicate mild distress, such as from a low-grade fever or anxiety, but it is not as concerning as an elevated temperature in this context.

Summary:

The fever (temperature 101°F) is the most concerning finding because it suggests an infection that could worsen the patient's condition, especially with type 2 diabetes, and requires immediate investigation and possible treatment.

Correct Answer: The patient reports trouble sleeping and loss of energy.

Belimumab (Benlysta) is a biologic medication used to treat Systemic Lupus Erythematosus (SLE) by inhibiting B-lymphocyte stimulator (BLyS), which plays a role in the activation of B cells involved in lupus.

As with any biologic medication, it can have side effects, and some of these may indicate a need for further evaluation.

Trouble sleeping and loss of energy are symptoms that could indicate a potential adverse reaction to the medication, such as an infection, or possibly a worsening of lupus symptoms or other systemic effects.

Given that biologic therapies can suppress immune function, infections (such as respiratory or urinary tract infections) are a concern, and patients on this medication should be closely monitored for signs of infection or changes in energy levels, which could signal either a side effect or an exacerbation of disease. Further evaluation is warranted.

Why the other options are incorrect:

The patient declines a flu shot via the intranasal route:

Belimumab does not specifically contraindicate the flu vaccine, but live attenuated vaccines (such as the intranasal flu vaccine) are generally not recommended for patients receiving immunosuppressive therapy like biologics. However, this option does not represent an immediate cause for concern or a need for urgent further evaluation.

The patient says they have not noticed a change in symptoms:

This is a normal response in the early stages of treatment. Belimumab may take time to show clinical improvements in symptoms. It is not uncommon for patients to not notice immediate effects, and it’s usually expected to take several weeks to months for noticeable changes in lupus symptoms.

The patient administers the medication in the subcutaneous tissue on the abdomen:

Belimumab is administered subcutaneously, and it is common to administer it in the abdomen or thigh. This is the correct route of administration, so no further evaluation is necessary here.

Summary:

A patient reporting trouble sleeping and loss of energy while on Belimumab should be further evaluated for possible adverse effects such as infections or disease exacerbation. The other options do not represent immediate concerns in the context of the prescribed treatment.

The correct answer is: D) Less than 7%

• 
  

  Hemoglobin A1C is a blood test that reflects the average blood glucose levels over the past 2-3 months. It is used to monitor long-term glucose control in people with diabetes.

  
  

• 
  

  The target for most adults with diabetes is an A1C of less than 7%. Achieving this target helps to reduce the risk of diabetes-related complications, such as nerve damage, kidney problems, and eye issues.

  
  

Why the Other Options Are Incorrect:

1. 
   

   A) Less than 4%:

   
   
   
   
   
   • 
     

     A hemoglobin A1C level of less than 4% would be dangerously low and indicate severe hypoglycemia. This is not a target for diabetes management.

     
     
   
   
   
   


2. 
   

   B) Greater than 6%:

   
   
   
   
   
   • 
     

     While a value above 6% may not be ideal for someone with diabetes, the goal is to keep the A1C level below 7% to reduce the risk of complications.

     
     
   
   
   
   


3. 
   

   C) Less than 10%:

   
   
   
   
   
   • 
     

     While an A1C less than 10% is better than higher levels, the optimal target is less than 7% for most patients to prevent complications. An A1C of 10% or higher suggests poor diabetes control.

     
     
   
   
   
   

Summary:

The target hemoglobin A1C for a diabetic patient is typically less than 7%. This is the goal recommended by the American Diabetes Association for most adults with diabetes to minimize long-term complications.

Correct Answer: The laboratory values are prolonged

Disseminated intravascular coagulation (DIC) is a serious condition that involves abnormal clotting throughout the bloodstream, leading to both excessive clotting and bleeding. DIC results in the consumption of clotting factors, which leads to prolonged clotting times.

Prolonged PT (Prothrombin Time): PT measures the time it takes for blood to clot. In DIC, because clotting factors are consumed faster than the liver can produce them, PT is prolonged.

Prolonged aPTT (Activated Partial Thromboplastin Time): aPTT measures the intrinsic pathway of the clotting cascade. Like PT, aPTT is prolonged in DIC due to the consumption of clotting factors.

Prolonged INR (International Normalized Ratio): INR is a standardized measure derived from PT. In DIC, INR will also be prolonged for the same reason as PT and aPTT — the consumption of clotting factors.

Why the other options are incorrect:

The laboratory values are decreased:

This is not correct. In DIC, clotting factors are consumed, not increased, so clotting times (PT, aPTT, INR) will be prolonged, not decreased.

The laboratory values are within the expected reference range:

This is not correct. DIC causes abnormal clotting and consumes clotting factors, leading to prolonged clotting times.

The laboratory values are the same as the previous test values:

This is not correct. The values in DIC will change, typically becoming prolonged as clotting factors are consumed.

Summary:

In disseminated intravascular coagulation (DIC), the PT, aPTT, and INR values are typically prolonged due to the consumption of clotting factors as a result of widespread clotting in the body.

Correct Answer: Difficulty with activity

The patient's symptoms of fatigue, pallor, progressive weakness, exertional dyspnea, headache, and tachycardia strongly indicate anemia, which is a common side effect of chemotherapy. Anemia leads to decreased oxygen-carrying capacity, directly impacting the patient’s ability to perform daily activities and causing difficulty with activity.

Addressing activity intolerance and the underlying cause of these symptoms (likely anemia) is a priority for improving the patient's overall function and quality of life.

Why the Other Options Are Less Priority:

Change in nutritional status:

While chemotherapy can affect appetite and nutritional intake, the symptoms described are more directly related to anemia rather than malnutrition. Nutritional concerns are important but secondary to addressing activity intolerance due to impaired oxygen delivery.

Feeling unable to control the disease process:

This relates to psychosocial needs, which are important but not the most urgent issue compared to addressing the physical symptoms impacting activity and quality of life.

Psychosocial issues dealing with the disease process:

Psychosocial support is essential for coping with cancer and its treatment, but the immediate priority is addressing the physical symptoms causing activity intolerance.

Nursing Priority:

The nurse should focus on managing the patient’s fatigue and activity intolerance by:

1. Monitoring hemoglobin levels.

2. Administering blood transfusions or erythropoiesis-stimulating agents as prescribed.

3. Encouraging energy conservation techniques (e.g., rest periods).

4. Promoting a balanced diet to support red blood cell production.

5. This will help alleviate the patient’s physical symptoms and improve their ability to perform activities.

Correct Answer: 1-2 weeks

The oliguric stage of acute kidney injury (AKI) typically lasts 1-2 weeks. During this stage, the kidneys are not able to effectively filter waste products from the bloodstream, and the patient may experience oliguria, or significantly reduced urine output.

This stage is characterized by a decrease in urine production and the retention of waste, leading to imbalances in electrolytes, acid-base status, and fluid volume.

The duration can vary, but generally, the oliguric phase lasts between 1 and 2 weeks, depending on the severity of the injury and the patient's response to treatment.

Why the other options are wrong:

1-3 days

This is incorrect because the oliguric phase typically lasts longer than just a few days. While some patients may progress through this stage more quickly, it usually lasts longer, around 1-2 weeks.

Few hours to 2 weeks

This option is not entirely wrong in that the stage could last anywhere from a few hours to two weeks, but it is too broad and not specific enough. The majority of patients will remain in the oliguric phase for 1-2 weeks, so this range may cause confusion.

12 months

This is incorrect because the oliguric phase of AKI does not last anywhere near that long. The oliguric stage is typically a short-term phase, lasting days to weeks, but not months. If the condition persists for such an extended period, it may indicate chronic kidney disease (CKD) or end-stage kidney disease (ESKD), not AKI.

Summary:

The oliguric phase in acute kidney injury usually lasts between 1-2 weeks, during which time kidney function is impaired, leading to reduced urine output and the accumulation of waste products. This stage requires close monitoring and intervention to correct electrolyte imbalances, fluid overload, and potential acidosis.

The correct duration of this phase is important for the timely identification of the transition to the diuretic phase, where the kidneys start to recover and produce more urine.

Correct Answer: 20-gauge midline catheter.

A midline catheter is the most appropriate intravenous access device (IVAD) for a patient requiring 3 to 4 weeks of IV antibiotics, as it is specifically designed for intermediate-term intravenous therapy (typically lasting from 1 to 4 weeks). Here’s why:

1. Duration of Therapy: Midline catheters are ideal for therapies lasting several weeks, as they are more durable and have a lower risk of complications compared to peripheral IV devices.

2. Gauge: A 20-gauge catheter is suitable for the administration of antibiotics, as it can handle the required flow rates without difficulty.

3. Comfort and Safety: Midline catheters are inserted into the upper arm and advanced until the tip reaches the basilic, cephalic, or brachial vein, providing reliable access with fewer insertion-related complications compared to peripheral devices.

Why the other options are incorrect:

16-gauge central venous: Central venous access is not necessary for antibiotic therapy unless the patient has poor peripheral access, requires multiple incompatible infusions, or needs central access for another reason (e.g., parenteral nutrition or hemodynamic monitoring). It is more invasive and has higher risks, such as infection and thrombosis.

18-gauge over-the-needle IVAD: While an 18-gauge peripheral IV catheter can be used for IV antibiotics, it is not suitable for 3 to 4 weeks of therapy due to the risk of phlebitis, infiltration, and frequent replacement (usually every 72–96 hours).

22-gauge steel-winged device: Steel-winged devices, often referred to as butterfly needles, are designed for short-term use (e.g., single-dose administration or blood draws). They are not appropriate for long-term IV therapy, as they are prone to dislodgement and tissue infiltration.

Summary:

For intermediate-term IV antibiotic therapy lasting 3 to 4 weeks, a 20-gauge midline catheter is the most appropriate choice. It provides reliable venous access with fewer risks and is specifically designed for this duration of treatment.